4 August 2020 - The Patented Medicine Prices Review Board's revised Guidelines will result in patients losing access to innovative new medicines, a reduction in the number of clinical trials in Canada, and reduced investment in the country's life sciences sector, according to a recent submission by Innovative Medicines Canada to the PMPRB.

"We remain deeply concerned about the impact the amended Patented Medicines Regulations will have on Canadians' access to affordable, innovative medicines, and on the country's ability to attract investment to our life-sciences sector," said IMC President Pamela Fralick. "As the COVID-19 crisis has shown, Canada's innovative medicines companies are vital to the health and well-being of all Canadians, and we need a regulatory environment that will help them to grow and thrive."

Read Innovative Medicines Canada press release